ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Synthesis and characterization of chitosan-functionalized nanostructured lipid carriers with temozolomide: cytotoxic effects and chromosomal instability in human glioblastoma cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Multiform glioblastoma (GBM) is the most aggressive primary brain tumor, associated with high heterogeneity, treatment resistance, and poor survival. Temozolomide (TMZ), although the main chemotherapeutic agent used, shows limited efficacy due to low solubility, chemical instability, and acquired resistance. In this context, nanostructured systems can enhance their antitumor efficacy. This study aimed to develop and characterize chitosan-functionalized nanostructured lipid carriers loaded with Temozolomide (NLCTQ), as well as to assess their biological activity in human glioblastoma cells (U87-MG). Lipid nanoparticles functionalized with chitosan were prepared by hot emulsification and sonication. Physicochemical characterization included DLS, zeta potential, FTIR, and HPLC for drug quantification and encapsulation efficiency. Biological activity was evaluated in U87-MG cells using the cell viability assay MTT and trypan blue, the comet assay, the spheroid model, fluorescence cell death, and the CBMN assay. The formulation presented a homogeneous nanometric size and positive zeta potential, although with moderate encapsulation efficiency (39%). Biological assays demonstrated that NLCTQ significantly reduced cell viability, overcoming the U87-MG cell line's resistance to TMZ by achieving cytotoxicity at doses up to 20 times lower than free TMZ. Additionally, NLCTQ promoted the formation of biomarkers of chromosomal instability, such as micronuclei, bridges, and nuclear buds, which may explain the observed cytotoxic effects. Together, the results indicate that TMZ nanoencapsulation in NLCTQ enhances its antitumor efficacy, representing a promising strategy to overcome the limitations of conventional chemotherapy in glioblastoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.